Researchers investigated the efficacy and safety of ixekizumab for up to 52 weeks in patients with active radiographic axial spondyloarthritis who were biologic disease-modifying antirheumatic drug-naive or tumor necrosis factor inhibitor-experienced.
Researchers analyzed the progression of spinal radiographic damage in patients with early axial spondyloarthritis.
Researchers evaluated the association between trabecular bone loss and disease activity measures in patients with axial spondyloarthritis.
The Assessment of SpondyloArthritis International Society sought to develop a global set of quality standards to help improve healthcare quality for adult patients with axial spondyloarthritis.
Researchers evaluated the effect of fibromyalgia on the clinical outcomes of biologics in patients with psoriatic arthritis.
Ixekizumab demonstrated superiority to adalimumab in achieving simultaneous joint and skin improvement in biologic-naive patients with active psoriatic arthritis, according to data from the phase 3b/4 SPIRIT Head-to-Head (H2H) study.
In a phase 3 study, researchers assessed the efficacy and safety of ixekizumab in patients with active nonradiographic axial spondyloarthritis.
Tumor necrosis factor inhibitors slow radiologic progression when compared to other drug classes in ankylosing spondylitis.
Researchers aimed to identify factors related to depressive symptoms in ankylosing spondylitis and comprehend their underlying associations.
Tildrakizumab-asmn demonstrated significant improvements to swollen and tender joint counts and pain in patients with active psoriatic arthritis (PsA), according to phase 2b interim results.